Inhibitor Therapeutics Inc (INTI) Stock Analysis
Verdict: AVOID
Severe cash burn with under 9 months of runway and negative equity creates extreme dilution risk despite clinical pipeline potential.
Investment score: 13/100
Analysis as of
Is Inhibitor Therapeutics Inc stock worth reviewing? The TradeMates thesis
The TradeMates model evaluates INTI as an AVOID due to zero revenue, an ongoing cash burn rate of $3.23M per year against $2.38M in cash (~8.8 months runway), negative equity of -$1.29M, and acute dilution risk.
7-factor investment score
- Valuation: 10/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 30/100 (weight 15%)
- Earnings Quality: 15/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 0/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
Inhibitor Therapeutics Inc opportunities and risks
What speaks for INTI
- Phase 2b clinical completion for SUBA-Itraconazole in basal cell carcinoma nevus syndrome
What speaks against INTI
- Critical cash runway constraint of approximately 8.8 months
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| INTI | n/a | 0.0x | n/a | 0.0% | 0.0% | -21.0% |
| CNSY | n/a | 3.3x | n/a | 89.6% | -620.7% | -168.1% |
| BIVI | n/a | 0.0x | n/a | 0.0% | 0.0% | -140.1% |
| PASG | n/a | 0.0x | 0.3x | 0.0% | 0.0% | -217.0% |
| MBRX | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -624.4% |
| SYBX | n/a | 0.0x | n/a | 0.0% | 0.0% | -28.3% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -168.1% |
Frequently asked questions about Inhibitor Therapeutics Inc (INTI)
Is INTI stock a good investment?
The TradeMates model rates Inhibitor Therapeutics Inc as AVOID with an investment score of 13/100. The TradeMates model evaluates INTI as an AVOID due to zero revenue, an ongoing cash burn rate of $3.23M per year against $2.38M in cash (~8.8 months runway), negative equity of -$1.29M, and acute dilution risk. This is algorithmic model output, not personal investment advice.
Is INTI stock a buy?
The TradeMates model verdict for INTI is AVOID with an investment score of 13/100. Treat this as a model signal to review, not a personal buy recommendation.